Missouri AG issues cease‑and‑desist to Eli Lilly over 340B data‑submission requirement
Missouri Attorney General Catherine Hanaway sent a cease‑and‑desist letter to Eli Lilly, ordering the company to stop requiring Missouri hospitals to provide extensive prescription‑claims data as a condition for 340B drug‑price discounts. The dispute began after Lilly suspended University of Missouri Health Care’s 340B pricing on July 2, 2026, when the health system refused to comply with the new policy that started earlier in 2026. MU Health Care temporarily agreed to supply the data while preserving its legal rights.
Why it matters
The AG warned that failure to comply could trigger enforcement under the Missouri Merchandising Practices Act, creating regulatory risk for Lilly and potentially affecting its 340B pricing revenue in the state. The letter also highlights broader concerns about data‑privacy costs for hospitals that rely on 340B discounts.
Key facts
- 1Missouri Attorney General Catherine Hanaway issued a cease‑and‑desist letter to Eli Lilly demanding the company end its claims‑data requirement for Missouri hospitals in the 340B program. kttn.com
- 2Eli Lilly suspended University of Missouri Health Care’s access to 340B pricing on July 2, 2026 after the health system refused to provide the required data. kttn.com
- 3Lilly’s policy, introduced earlier in 2026, required all 340B entities to submit detailed claims data for every dispensation of any Lilly product. komu.com
- 4MU Health Care temporarily agreed to provide the data while preserving its legal rights. kttn.com
- 5The AG warned non‑compliance could lead to enforcement under the Missouri Merchandising Practices Act. kttn.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.